Clinical Trials
17 trialsNCT07630961 2026-06-05
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Novartis
Phase 1 Not yet recruiting
NCT07623369 2026-06-03
A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors
Huahui Health
Phase 1 Not yet recruiting
NCT07623642 2026-06-03
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
GV20 Therapeutics
Phase 2 Not yet recruiting
NCT07581314 2026-05-12
Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
Telomir Pharmaceuticals, Inc.
Phase 1/2 Not yet recruiting
NCT07556848 2026-04-30
A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3 Not yet recruiting
NCT07544056 2026-04-22
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
BeBetter Med Inc
Phase 2/3 Not yet recruiting
NCT07545122 2026-04-22
CT-202
Context Therapeutics Inc.
Phase 1 Not yet recruiting
NCT02802423 2026-04-13
Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.
BioLite, Inc.
Phase 1/2 Not yet recruiting
NCT07487519 2026-03-23
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
Shanghai Henlius Biotech
Phase 2 Not yet recruiting
NCT07272642 2026-02-25
DUNP19
Radiopharm Theranostics, Ltd
Phase 1 Not yet recruiting
NCT07423117 2026-02-20
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
IntoCell, Inc
Phase 1 Not yet recruiting
NCT07246759 2025-11-24
NEUTROFLOW
OncoHost Ltd.
Not yet recruiting
NCT07080619 2025-09-11
SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
Tianjin ConjuStar Biologics Co., Ltd.
Phase 2 Not yet recruiting
NCT06724263 2024-12-09
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
Tasly Biopharmaceuticals Co., Ltd.
Phase 2 Not yet recruiting
NCT06586866 2024-09-19
JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases
JenKem Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT05698238 2023-03-15
CAMP1
Mabpro, a.s.
Phase 1 Not yet recruiting
NCT04301739 2020-03-12
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
Shanghai Henlius Biotech
Phase 3 Not yet recruiting